PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML

Detalles Bibliográficos
Autores principales: Patel, Anand, Michaelis, Laura, Schiller, Gary, Swords, Ronan, Morris, Lawrence E., Carvajal, Luis A., Bray, Gordon, Olek, Elizabeth A., Cutler, Richard, Dimartino, Jorge, Stein, Eytan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429830/
http://dx.doi.org/10.1097/01.HS9.0000974380.14929.94
Descripción
Sumario:

Ejemplares similares